<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR352.html">Part 352
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 352.60  Labeling of permitted combinations of active ingredients.
                            </h3>
                            <p class="depth0">Statements of identity, indications, warnings, and directions for  use, respectively, applicable to each ingredient in the product may be  combined to eliminate duplicative words or phrases so that the resulting  information is clear and understandable.</p><p class="depth1"><em>(a)</em> Statement of identity. For a combination drug product that has  an established name, the labeling of the product states the established  name of the combination drug product, followed by the statement of  identity for each ingredient in the combination, as established in the  statement of identity sections of the applicable OTC drug monographs.  For a combination drug product that does not have an established name,  the labeling of the product states the statement of identity for each  ingredient in the combination, as established in the statement of  identity sections of the applicable OTC drug monographs.</p><p class="depth1"><em>(b)</em>, may also be used, as provided by Sec.  330.1(c)(2) of this chapter, subject to the provisions of section 502 of  the Federal Food, Drug, and Cosmetic Act (the act) relating to  misbranding and the prohibition in section 301(d) of the act against the  introduction or delivery for introduction into interstate commerce of  unapproved new drugs in violation of section 505(a) of the act.</p><p class="depth2"><em>(1)</em> In addition, the labeling of the product may contain any of the  ``other allowable statements'' that are identified in the applicable  monographs.</p><p class="depth2"><em>(2)(i)</em> of this chapter should be  used. For products marketed as a lip protectant, the indication in Sec.  352.52(f)(1)(ii) should be used.</p><p class="depth1"><em>(c)(3)</em> of this chapter is not required for permitted combinations  containing a sunscreen and a skin protectant identified in Sec.  352.20(b). For products marketed as a lip protectant or lipstick, Sec.  352.52(f)(1)(iii), (f)(1)(iv) (except ``Keep out of eyes,'' which may be  omitted), and (f)(1)(vi) apply.</p><p class="depth1"><em>(d)(4)</em> applies.  [64 FR 27687, May 21, 1999, as amended at 68 FR 33380, June 4, 2003]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
